Articles

Amgen NASDAQ: AMGN pharmaceutical powerhouse just released a report stating positive performance results for Pivotal Postmenopausal Osteoporosis Trial for denosumab.

Trial met primary endpoint of Diminishing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation was excited." I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the premier fully human monoclonal antibody in late stage clinical development that particularly targets RANK Ligand, an important regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being considered for its ability to inhibit every stage of osteoclast activity by a targeted mechanism. Denosumab is being researched in a range of bone loss conditions including postmenopausal osteoporosis, rheumatoid arthritis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to delay bone metastases and stop and treat bone destruction across many stages of cancer.

Often referred to as the "silent epidemic", osteoporosis is a global problem illness that is increasing in significance as the population of the world both ages and increases. WHO, The World Health Organization has recently claimed osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical companies to help combat this horrendous disease.

According to Amgen the economic burden of osteoporosis is comparable to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Pharmacist-clinical have been researching prescriptions drugs to help patient who experience serious side effects. These products are developed simultaneously the medications that aid in the treatment of the primary illness. The fact that research is available to help anticipate the potential effects and interactions drugs have with each other is awesome.

These medicines are prescribed to prevent and treat osteoporosis. A few prescriptions increase bone thickness or slow the rate of bone loss. Even small amounts of new bone growth may diminish the danger of broken bones. It is essential that you take calcium and vitamin D, exercise and eat well when you take osteoporosis prescriptions.